← Leaderboards
Haijiao Zhang
Oregon Health & Science University
$1,696,427
Attributed
$1,696,427
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $378.4K · FY2019–25$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,696,427 · 3
By mechanism
R00$746,999 · 1
R37$745,144 · 1
K99$204,284 · 1
Top collaborators
No co-investigators on record.
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Jeffrey Wallace Tyner$13,872,769
- Anupriya Agarwal$8,829,719
- Julia E Maxson$5,322,132
- Theodore Paul Braun$2,536,053
- Bill H Chang$918,328
Others in their field
Other Emerging Leaders on “Overexpression”
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$9,634,868
- Robert Nicol · Broad Institute, Inc.$7,498,771
- Michael R Tadross · Duke University$6,418,169
- Terry Roemer · Prokaryotics, Inc.$5,773,697
- Yi Ye · New York University$5,437,303
- Montserrat C Anguera · University Of Pennsylvania$5,285,297
Research focus
OverexpressionNovel TherapeuticsDrug ResistanceHematologic NeoplasmsMediatingMutationChemotherapyDoseGrowthCellsLeukemiaLeukemic CellClustered Regularly Interspaced Short Palindromic RepeatsMolecularCandidate Disease GeneCell LineCombined Modality TherapyCytarabineBone MarrowGenesApoptosisCell ProliferationIn VivoPathogenesis
Grant awards (7)
Characterization of NUP205 as a haploinsufficient essential gene for the treatment of hematopoietic malignancies$366,739
R37 · FY2025 · CA · contact PI
Characterization of NUP205 as a haploinsufficient essential gene for the treatment of hematopoietic malignancies$378,405
R37 · FY2024 · CA · contact PI
Characterizing the pathogenesis and targeted therapeutics of Wilms' Tumor 1 (WT1) mutations in AML$249,000
R00 · FY2023 · CA · contact PI
Characterizing the pathogenesis and targeted therapeutics of Wilms' Tumor 1 (WT1) mutations in AML$249,000
R00 · FY2022 · CA · contact PI
Characterizing the pathogenesis and targeted therapeutics of Wilms' Tumor 1 (WT1) mutations in AML$248,999
R00 · FY2021 · CA · contact PI
Characterizing the pathogenesis and targeted therapeutics of Wilms' Tumor 1 (WT1) mutations in AML$102,142
K99 · FY2020 · CA · contact PI
Characterizing the pathogenesis and targeted therapeutics of Wilms' Tumor 1 (WT1) mutations in AML$102,142
K99 · FY2019 · CA · contact PI